Evaluation of combined nedaplatin and docetaxel therapy for human head and neck cancer in vivo

Anticancer Research

Volumn 26, Issue 2 A, 2006, Pages 989-994

  Yamada, Hajime ^a   Maki, Hideo ^a   Takeda, Yukihiro ^a   Orita, Satoshi ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

Docetaxel; Head and neck cancer; Nedaplatin

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; NEDAPLATIN;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEAD AND NECK CANCER; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CELL LINE, TUMOR; CISPLATIN; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33645833695     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Furuse K, Fukuoka M, Kurita Y et al: A phase II clinical study of cis-diammine glycolato platinum, 254-S, for primary lung cancer. Jpn J Cancer Chemother 19: 879-884, 1992.
2. Furuse K, Fukuoka M, Asamoto H et al: A randomized comparative study of 254-S plus vindesine (VDS) vs. cisplatin (CDDP) plus VDS in patients with advanced non-small cell lung cancer (NSCLC). Jpn J Cancer Chemother 19: 1019-1026, 1992.
3. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S and Ohta K: An early phase II study of cis-diammine glycolato platinum, 254-S, for head and neck cancers. Jpn J Cancer Chemother 19: 863-869, 1992.
4. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K and Komiyama K: A late phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers. Jpn J Cancer Chemother 19: 871-877, 1992.
5. Akaza H, Togashi M, Nishio Y et al: Phase II study of cis-diammine (glycolato) platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. Cancer Chemother Phamacol 31: 187-192, 1992.
6. Taguchi T, Wakui A, Nabeya K et al: A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group. Cancer Chemother Phamacol 19: 483-488, 1992.
7. Kato T, Nishimura H, Yakushiji M, Noda K et al: Phase II study of 254-S (cis-diammine glycolato platimum) for gynecological cancer. Jpn J Cancer Chemother 19: 695-701, 1992.
8. Noda K, Ikeda M, Yakushiji M et al: A phase II clinical study of cis-diammine glycolate platinum, 254-S, for cervical cancer of the uterus. Jpn J Cancer Chemother 19: 885-892, 1992.
9. Bissery MC, Guénard D, Guéritte-Voegelein F and Lavelle F: Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 57: 4845-4852, 1991.
10. Tanaka M, Obata T and Sasaki T: Evaluation of antitumor effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo. Eur J Cancer 32A: 226-230, 1996.
11. Taguchi T, Mori S, Abe R et al: Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer. Jpn J Cancer Chemother 21: 2625-2632, 1994.
12. Adachi I, Watanabe T, Takashima S et al: A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 73: 210-216, 1996.
13. Kudo S, Hino M, Fujita A et al: Late phase II clinical study of RP56976 (docetaxel) in patients with non-small cell lung cancer. Jpn J Cancer Chemother 21: 2617-2623, 1994.
14. Onoshi T, Watanabe K, Furuse K et al: Late phase II trial of RP56976 (docetaxel) in patients with non-small-cell lung cancer. Jpn J Cancer Chemother 22: 59-65, 1995.
15. Inuyama Y, Kataura A, Togawa K et al: Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer. Jpn J Cancer Chemother 26: 107-116, 1999.
16. Taguchi T, Sakata Y, Kanamaru R et al: Late phase II clinical study of RP56967 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group Trial (group A). Jpn J Cancer Chemother 25: 1915-1942, 1998.
17. Markman M, Kennedy A, Webster K et al: Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol 19: 1901-1905, 2001.
18. Muro K, Hamaguchi T, Ohtsu A et al: A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15: 955-959, 2004.
19. Uchida N, Kasai H, Takeda Y, Maekawa R, Sugita K and Yoshioka T: Synergy of the combination of nedaplatin with etopside in murine and human lung carcinoma. Anticancer Res 18: 247-252, 1998.
20. Uchida N, Takeda T, Hojo K, Maekawa R, Sugita K and Yoshioka T: Sequence-dependent antitumor efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with 5-fluorouracil on in vivo murine tumor model. Eur J Cancer 34: 1796-1801, 1998.
21. Takeda Y, Kasai H, Uchida N, Yoshida H, Maekawa R, Sugita K and Yoshioka T: Enhanced antitumor efficacy of nedaplatin with 5-fluorouracil against human squamous carcinoma xenografts. Anticancer Res 19: 4059-4064, 1999.
22. Uchida N, Yoshida H, Yamada H, Wada T et al: Combination chemotherapy with nedaplatin and cyclophosphamide in human ovarian cancer model. Jpn J Cancer Res 90: 887-894, 1999.
23. Matsumoto M, Takeda Y, Maki H, Hojo K et al: Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer. Jpn J Cancer Res 92: 51-58, 2001.
24. Obasaju CK, Johnson SW, Rogatko A et al: Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin Cancer Res 2: 549-552, 1996.
25. Kearns CM and Egorin MJ: Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy. Semin Oncol 24: S2-91-S2-96, 1997.
26. Yamada H, Uchida N, Maekawa R and Yoshioka T: Sequence-dependent antitumor efficay of combination with nedaplatin, a newly developed platinum, and paclitaxel. Cancer Lett 172: 17-25, 2001.
27. Houchens DP and Ovejera AA: Experimental therapy in subcutaneous transplants. In: The Nude Mouse in Oncology Research, Boven E, Winograd S (eds.), CRC Press, Boca Raton, FL, USA, pp. 134-143, 1991.
28. Koenuma M, Kasai H, Uchida N et al: Antitumor activity of a new platinum complex, nedaplatin. Clin Rep 29: 3213-3222, 1995.
29. Uchida N, Yamada H, Maekawa R and Yoshioka T: Combination chemotherapy of paclitaxel followed by nedaplatin for human ovarian cancer. Jpn J Cancer Chemother 29: 1943-1949, 2002.
30. Calvert AH: A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel. Semin Oncol 24: S2-85-S2-91, 1997.
31. Kurita H, Yamamoto E, Nozaki S et al: Multicenter phase I trial of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma. Oral Oncol 40: 1000-1006, 2004.
32. Kennedy MJ, Zahurak ML, Donehower RC et al: Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte-colony-stimulating factor in women with previously treated metastatic breast cancer. J Clin Oncol 14: 783-791, 1996.
33. Holmes FA, Madden T, Newman RA et al: Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14: 2713-2721, 1996.
34. Rowinsky EK, Gilbert MR, McGuire WP et al: Sequence of taxol and cisplatin: a phase I and pharmacological study. J Clin Oncol 9: 1692-1703, 1991.
35. Kubota K, Watanabe K, Kunitoh H et al: Phase III randomized trail of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22: 254-261, 2004.
36. Glisson BS, Murphy BA, Frenette G, Khuri FR and Forastiere AA: Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 20: 1593-1599, 2002.